We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
HHS is posting online prices of more than four dozen drugs in several therapeutic classes with the intention of fostering competition that will encourage pharmaceutical firms to lower prices for the products.
HHS is posting online prices of more than four dozen drugs in several therapeutic classes with the intention of fostering competition that will encourage pharmaceutical firms to lower prices for the products.
Aggressive substitution of generics in place of their brand counterparts can be a major source of savings for state Medicaid programs, according to a recent report issued by the Centers for Medicare & Medicaid Services (CMS).
The Government Accountability Office (GAO) released its long-awaited recommendations last week for the establishment of a nationalized competitive bidding system for durable medical equipment (DME).
HHS should try to recover the government salary paid to the former administrator of the Centers for Medicare & Medicaid Services (CMS), who is accused of concealing from Congress higher cost estimates, technical assistance and data relevant to the Medicare prescription drug bill, according to a new legal opinion from the Government Accountability Office (GAO).
The Bush administration is asking a federal court to throw out a lawsuit by several House Democrats that seeks to force HHS to release cost estimates it made before the passage of last year’s Medicare prescription drug bill.
The chairman of the Senate Finance Committee, which has partial legislative jurisdiction over the Medicare program, is stepping up his surveillance of drug companies that repeatedly violate corporate integrity agreements they have entered into with the agency.
Sen. Chuck Grassley (R-Iowa), the chairman of the Senate Finance Committee, which has partial legislative jurisdiction over the Medicare program, is stepping up his surveillance of drug companies that repeatedly violate corporate integrity agreements they have entered into with the agency.
HHS and the FDA said they would “vigorously” defend themselves against allegations that the agencies are not acting quickly enough to establish a program that would allow the legal importation of prescription drugs from Canada.
A ranking House Democrat has asked HHS Secretary Tommy Thompson to reconsider his decision to abide by the National Institutes of Health’s (NIH’s) finding that it would not intervene to authorize generic competition with Abbott Laboratories’ AIDS drug Norvir.